AzTrials
AzTrials

Shoulder PainPhase 2/3RCTNCT04115449

Effect of Intravenous Dexmedetomidine on Patient Discomfort in Laparoscopic Cholecystectomy Under Spinal Anesthesia.

A Phase 2/3 study testing Dexmedetomidine and normal saline in people with Shoulder Pain, run by Theodor Bilharz Research Institute at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Laparoscopic cholecystectomy (LC) has been routinely performed under general anesthesia despite the several disadvantages of general anesthesia compared to regional anesthesia. There are multiple reports that have been published regarding the feasibility of spinal anesthesia for LC associated with many problems such… Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Shoulder Pain
What is being tested?
Dexmedetomidine and normal saline
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
1 siteEgypt
Study dates
15 Nov 2019to Jul 2021
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • ASA 1-2.
  • Patients undergoing elective laparoscopic Cholecystectomy with estimated pneumoperitoneum time of 60 to 90 min.

Who cannot join

  • Pregnancy.
  • Lactating women.
  • Any contraindication to spinal anesthesia e.g. Bleeding diathesis, infection at the puncture site, patient on anticoagulants or preexisting neurological deficits in lower extremities.
  • Patients on α2-adrenergic receptors antagonists, calcium channel blockers, or angiotensin-converting enzyme inhibitors.
  • Patients known allergic to bupivacaine or dexmedetomidine

Trial locations and contacts

1 site in 1 country.

Moshira S Mohamed, MD contact

202-1227206511

moshira.amer83@gmail.com

Egypt1 site, 1 recruiting
  • Theodor Bilharz research institute

    Cairo, 02

    Moshira Amer, moshira.amer83@gmail.com

    Recruiting

Other trials in Egypt

About this study

Official title: Effect of Intravenous Dexmedetomidine on Patient Discomfort in Laparoscopic Cholecystectomy Under Spinal Anesthesia. A Randomized Control Study.

Laparoscopic cholecystectomy (LC) has been routinely performed under general anesthesia despite the several disadvantages of general anesthesia compared to regional anesthesia.

There are multiple reports that have been published regarding the feasibility of spinal anesthesia for LC associated with many problems such as referred shoulder pain secondary to intra-abdominal pneumoperitoneum; patient anxiety, pain, and discomfort; and inadequate sedation.The aim of our study is to prospectively observe the feasibility of using intravenous dexmedetomidine to abolish patient discomfort and shoulder pain, thus making the patient more comfortable without causing excessive sedation and respiratory depression.

Read the detailed description

This is a prospective, randomized double blinded control study which will be conducted in department of anesthesia and surgical Intensive care unit at Theodor Bilharz Research Institute after approval by research ethics committee and patient informed consent. 40 patients will be enrolled in the study and divided into two groups 20 patients each ; either (Dexa group (D) or Control group (C).

Anesthesia Technique:

A preoperative assessment, including a history, physical examination, review of laboratory data, and assignment of ASA classification will be performed on all patients prior to the procedure. Anesthesia and procedural consent will be obtained.

After premedication with i.v. midazolam 2 mg , patients will be transferred to the operating theatre. Ringer's solution 500 ml will be given over 15 min, and patients will be premedicated with intravenous ondensetron 4 mg and intravenous atropine 0.2 mg.

IN DEXA GROUP:

Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes then Spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Than manintance dose of dexmedetomidine will be titrated from (0.2- 0.6 mcg /kg/ min) according to the patient discomfort.In CONTROL GROUP:

Normal Saline as a placebo will be infused over a period of ten minutes then spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Then the placebo will be titrated according to patient discomfort.

In BOTH GROUPS:

After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale (0 = no paralysis; 1 = unable to raise extended leg; 2 = unable to flex knee; 3 = unable to flex ankle) and recorded 10 min after placement in the supine position. Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask.Heart rate (HR), non-invasive mean blood pressure (MBP), and respiratory rate will be monitored preoperatively, during dexmedetomidine infusion, after completion of infusion i.e. before spinal anaesthesia, after spinal anaesthesia, during creation of pneumoperitoneum, thereafter every 10 minutes, after desufflation and on admission to Post Anaesthesia Care Unit (PACU) If the systolic arterial pressure decreased to below 90 mm Hg or if mean arterial pressure decreased (MAP) 20% from baseline, ephedrine bolous will be given i.v. If heart rate decreased to, 45 beats min, i.v. atropine 0.5 mg will be administered.

Discomfort and shoulder pain will be assessed either by verbal complaint by the patient or by facial and body expression. Supplemental doses of fentanyl 25 μg were given if the patient is discomfort or in pain.

Any patient shall be converted to general anesthesia at any time intraoperatively due to persistent pain or discomfort despite administration of intravenous analgesics or sedatives or surgical procedure related indication.

Data Collection

  1. Age
  2. Sex
  3. BMI
  4. ASA
  5. Abdominal discomfort
  6. Referred shoulder pain
  7. Arterial Blood pressue
  8. Heart rate
  9. Intraoperative Nausea/vomiting
  10. Respiratory depression is defined as respiratory rate < 8 bpm.
  11. Supplement of fentanyl
  12. Conversion to general anesthesia
  13. The severity of pain will be graded as nil, mild, moderate and severe.
  14. Sedation level will be evaluated according to a four-point rating scale. 1, Patient fully awake; 2, patient somnolent but responds to verbal commands; 3, patient somnolent but responds to tactile stimuli; 4, patient asleep but responds to pain
  15. The overall degree of patient satisfaction will be assessed using a three-point scale (good, moderate, and bad) on the first postoperative day.
  16. Time of complete regression of spinal anaesthesia,
  17. Post-operative complications: Nausea and Vomiting (PONV), Urine retention and Postdural puncture headache.

Statistical analysis Statistical analysis will be per-formed using the GraphPadInStat software package (GraphPad, San Diego, CA).The categorical factors are represented by the number and frequency (%) of cases. The continuous variables will represented by measures of central frequency and standard error. The statistical analysis was done by using unpaired t-test and Chi-square. p< 0.05 was considered statistically significant.

This is fourty patients will be prospectively enrolled for each study of patients who had been diagnosed to be able to reject the null hypothesis that the population means of the groups are equal with Power calculations suggested that a minimum of 16 subjects per group was required to detect 10% difference in arterial pressure between groups (taking type I or α error of 5%, type II or β error of 20% and Standard Deviation=10). To be on a safer side, 20 patients were included in each group (n=20).

Conditions
Shoulder Pain
Being tested
Dexmedetomidine, normal saline
Keywords
dexmedetomidine, shoulder pain, spinal anesthesia.
Medical subject headings
Shoulder Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DexmedetomidineDrug

    Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes

  • normal salineDrug

    Normal Saline as a placebo will be infused over a period of ten minutes

Study groups in NCT04115449
Study groupRoleWhat they receive
Dexa groupExperimentalSpinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Than manintance dose of dexmedetomidine will be titrated from (0.2- 0.6 mcg /kg/ min) according to the patient discomfort. After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale. Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask.
Receives: Drug: Dexmedetomidine
Control groupPlacebo comparatorNormal Saline as a placebo will be infused over a period of ten minutes then spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Then the placebo will be titrated according to patient discomfort. After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale.Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask.
Receives: Drug: normal saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraopertive shoulder pain

    The severity of pain will be graded as nil, mild, moderate and severe.

    Measured: 60-90 minutes

Secondary outcomes (1)
  1. Number of intraoperative hypoxic episodes

    (Spo2 ≤95 %)

    Measured: 60-90 minutes.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Oct 2019
  2. Study start15 Nov 2019
  3. Primary completionMay 2021 (estimated)
  4. Study completionJul 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
This is a prospective, randomized double blinded control study which will be conducted in department of anesthesia and surgical Intensive care unit at Theodor Bilharz Research Institute after approval by research ethics committee and patient informed consent. 40 patients will be enrolled in the study and divided into two groups either (Dexa group (D) or Control group (C).
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04115449
Sponsor's protocol ID
TBRI
Acronym
RCT
Status last verified
Apr 2021
First submitted
2 Oct 2019
Last updated
2 Apr 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data available for the participant will be: Age, Sex, BMI and ASA classification. these data will available for other researchers. other personal data won't be shared to ensure patient privacy.

Publications

  • Donmez T, Erdem VM, Uzman S, Yildirim D, Avaroglu H, Ferahman S, Sunamak O. Laparoscopic cholecystectomy under spinal-epidural anesthesia vs. general anaesthesia: a prospective randomised study. Ann Surg Treat Res. 2017 Mar;92(3):136-142. doi: 10.4174/astr.2017.92.3.136. Epub 2017 Feb 24.

    PubMed 28289667

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Dexmedetomidine and normal saline in people with Shoulder Pain, run by Theodor Bilharz Research Institute at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 2 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Moshira S Mohamed, MD (202-1227206511, moshira.amer83@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intraopertive shoulder pain (time frame: 60-90 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04115449, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in